Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Total Non-Current Liabilities over the past 11 years, most recently at $458.0 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 62.58% to $458.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $458.0 million through Dec 2025, down 62.58% year-over-year, with the annual reading at $458.0 million for FY2025, 62.58% down from the prior year.
  • Total Non-Current Liabilities was $458.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $1.2 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $1.2 billion in Q4 2024 and troughed at $196.2 million in Q2 2021.
  • The 5-year median for Total Non-Current Liabilities is $528.4 million (2021), against an average of $676.5 million.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 464.18% in 2022 and then crashed 71.16% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $598.8 million in 2021, then surged by 98.41% to $1.2 billion in 2022, then crashed by 70.27% to $353.3 million in 2023, then skyrocketed by 246.47% to $1.2 billion in 2024, then tumbled by 62.58% to $458.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Total Non-Current Liabilities are $458.0 million (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).